Status:

COMPLETED

A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function

Lead Sponsor:

Idorsia Pharmaceuticals Ltd.

Conditions:

Healthy

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

Two-part Phase 1 study to assess the effect of single therapeutic and supra-therapeutic doses of lucerastat on the QT/QTc interval duration in healthy subjects (Part A: Pilot study; Part B: TQT study)

Eligibility Criteria

Inclusion

  • Part A only:
  • \- Healthy male subjects aged between 18 and 55 years.
  • Part B only:
  • Healthy male and female subjects aged between 18 and 55 years.
  • Women of childbearing potential must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day 1 pre-dose of the first period. They must consistently and correctly use a highly effective method of contraception, or be sexually inactive, or have a vasectomized partner.
  • Women of nonchildbearing potential (i.e., postmenopausal, XY genotype, Turner syndrome, uterine agenesis).
  • Part A and B:
  • Signed informed consent prior to any study-mandated procedure.
  • Body mass index of 18.0 to 30.0 kg/m2 (inclusive) at Screening. Body weight at least 50.0 kg at Screening and prior to first study treatment administration.
  • Healthy on the basis of medical history, physical examination, cardiovascular assessments and clinical laboratory tests.

Exclusion

  • Part B only:
  • Known hypersensitivity to moxifloxacin or any of its excipients.
  • Pregnant or lactating women.
  • Women planning to become pregnant.
  • Part A and B:
  • Previous exposure to lucerastat.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • History or presence of rhythm disorders.

Key Trial Info

Start Date :

February 14 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 22 2019

Estimated Enrollment :

44 Patients enrolled

Trial Details

Trial ID

NCT03832452

Start Date

February 14 2019

End Date

April 22 2019

Last Update

October 31 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

QPS Netherlands B.V.

Groningen, Netherlands, 9713

A Study in Healthy Subjects to Investigate Whether Administration of Lucerastat Can Affect Normal Heart Function | DecenTrialz